Access cutting-edge newly diagnosed multiple myeloma (ndmm) treatment through this phase 3 clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Denver location
Preparing your pre-screening questions…
Access newly diagnosed multiple myeloma (ndmm) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related newly diagnosed multiple myeloma (ndmm) treatment provided free
Check if you qualify for this newly diagnosed multiple myeloma (ndmm) clinical trial in Denver, CO
No-Cost Study Care
Local to Denver
Convenient for CO residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete response (CR) rate at 9 months as assessed by Blinded Independent Central Review (BICR), in participants with TE NDMM. Study details include: * The study duration is estimated to be up to 13 years from the date the first participant is randomised. * For participants in Arm A (AZD0120), the total duration of participant follow-up will be 15 years (including a Long Term Follow-up study) after the last participant has received the AZD0120 infusion. * The treatment duration will be:- Arm A (AZD0120): lymphodepletion over 3 days, a single-day infusion of AZD0120, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. * Arm B (ASCT): conditioning therapy over 24 to 48 hours, ASCT, followed by a maximum of 2 years lenalidomide monotherapy maintenance treatment. Disclosure Statement: This is an open-label, randomised study with 2 treatment arms.
Sponsor: AstraZeneca
Yes, this clinical trial (NCT07735637) has an active research site in Denver, CO that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for newly diagnosed multiple myeloma (ndmm) treatment options in Denver, CO, this clinical trial (NCT07735637) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Denver research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced newly diagnosed multiple myeloma (ndmm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all newly diagnosed multiple myeloma (ndmm) clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Denver — not just this study.
Browse Multiple Myeloma Trials in Denver →